Micron Biomedical Secures $16 Million in Series A3 Financing to Expand Needle-Free Vaccine Technology

ATLANTA, Jan. 16, 2025 – Micron Biomedical, a pioneering company developing groundbreaking needle-free technology for drugs and vaccines using dissolvable microarrays, has announced a major financial milestone with a Series A3 financing round of over $16 million. This brings the total Series A investment to more than $33 million, accelerating Micron Biomedical’s commercial manufacturing capabilities. Leading this round are J2 Ventures and the Global Health Investment Corporation (GHIC).

Micron Biomedical’s Investment and Global Health Impact

Labeeb Abboud, CEO of GHIC, underscores the strategic importance of Micron Biomedical’s technology, stating, “There is a critical global need to move beyond needle-based delivery of medications and vaccines. Micron Biomedical is leading the charge with its innovative microarray technology, addressing a wide range of health challenges.”

This investment highlights the significant progress Micron Biomedical has made in improving access to vital health interventions. The funding will further support Micron Biomedical’s expansive research and development, bringing needle-free drug and vaccine administration closer to reality.

Recent Developments at Micron Biomedical

In recent months, Micron Biomedical has received notable recognition for its groundbreaking work:

• A $3.7 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop needle-free vaccines against Disease X.
• A $2 million winner in the Biomedical Advanced Research and Development Authority’s (BARDA) Patch Forward competition for mRNA-based broad-protecting flu vaccines.
• A $7.5 million grant from the Bill & Melinda Gates Foundation for a needle-free measles/rubella vaccine.

These grants mark crucial milestones in Micron Biomedical’s journey towards clinical trials and commercialization of its technologies. The company is now poised for its first Phase 2 clinical trial, a significant step towards delivering needle-free vaccines.

Technological Advancements in Microarray Technology

Micron Biomedical’s core technology is a dissolvable microarray platform designed for easy, painless drug and vaccine administration. This innovative system promises to improve access to medications and vaccines for underserved populations worldwide. Key benefits include:

• Elimination or reduction of the need for cold chain transport and storage.
• Patient preference and convenience in drug and vaccine administration.
• Enhanced safety and efficacy of treatments.
• Improved patient compliance.

By leveraging this technology, Micron Biomedical aims to transform the landscape of global healthcare, making essential treatments more accessible and convenient.

Partnerships and Collaborations

Micron Biomedical maintains strong partnerships with various entities in the pharmaceutical and biotech sector, as well as private and public organizations. Notable partners include:

• Pharmaceutical and biotech companies.
• Bill & Melinda Gates Foundation.
• Centers for Disease Control and Prevention (CDC).
• PATH.
• Georgia Research Alliance.

These collaborations demonstrate the company’s commitment to addressing pressing global health challenges and delivering high-impact innovations.

Conclusion

Micron Biomedical’s recent financing round signifies a pivotal moment in its mission to revolutionize drug and vaccine administration. The company’s innovative microray technology represents a significant leap forward in making essential treatments accessible, convenient, and effective for all patients.

“The financial support from GHIC and J2 Ventures will enable us to accelerate the development and commercialization of our microarray technology,” says Steve Damon, CEO of Micron Biomedical. “This investment will significantly boost our efforts to improve health outcomes and global access to critical medicines and vaccines.”

As Micron Biomedical continues to make strides in innovative biomedical Advancements, it is poised to make a profound impact on global health. Stay tuned for further developments in this groundbreaking field.

About Micron Biomedical
Micron Biomedical is the leading provider of dissolvable microarray-based drug and vaccine administration technology. Its mission is to improve global access to essential medicines and vaccines through painless, self-administered treatments. For more information, visit micronbiomedical.com.

Join the conversation by commenting below or share this article on your social media channels. Let us know what you think about Micron Biomedical’s innovative approach to healthcare technology. Subscribe to our newsletter for updates on the latest developments in global health innovation.